Q2 2024 · 13F-HR
M28 Capital Management LPholdings as filed
Filed 2024-08-13 · accession 0000902664-24-005090
$77.1M
Reported value
11
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $30.8M | 39.9% | 6,164,548 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $10.2M | 13.2% | 9,248,250 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $8.3M | 10.8% | 385,680 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $7.9M | 10.3% | 1,856,117 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $4.2M | 5.39% | 110,400 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $3.5M | 4.56% | 185,100 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $3.1M | 3.98% | 121,200 | Common | SOLE |
| 231269309 | CRIS | CURIS INC | $2.9M | 3.77% | 421,951 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $2.9M | 3.73% | 161,600 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS IN | $1.8M | 2.27% | 67,400 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $1.7M | 2.19% | 1,019,498 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.